Ten post jest także dostępny w języku: polski
Thanks to the adoption by the Committee for Medicines for Human (CHMP) belonging to the European Medicines Agency (EMA), two recommendations in April 2021 will increase the production capacity and supply of each of the companies producing vaccines against COVID-19. We are talking about the Pfizer/BioNTech and Moderna.
Acceleration of production and a new production line
The first recommendation is to increase the batch size of COVID-19 vaccines and thus scale up the process at Pfizer’s vaccine production facility in Puurs, Belgium. Moreover, this recommendation will have a decisive impact on the supply of Comirnata (a vaccine developed by BioNTech and Pfizer in the European Union), as it gives companies permission to accelerate production, which translates into an improvement in the distribution process between EU countries.
The second important recommendation approved by the EMA is the opening of a new production line for the filling of Moderna COVID-19 vaccines. The new line will be located in Rovi, Spain. The production line will make it possible to increase the activities related to filling the finished product. It is worth adding that thanks to this, the plant will intensify the production process of the active substance and synchronize its activities with the Lonza plant, approved in March, located in Visp, Switzerland.
What will this mean for Poland?
The European Medicines Agency is constantly striving to improve the COVID-19 vaccine production and distribution sector by approving new reforms and through constant dialogue with the manufacturers of individual vaccines. As a result, citizens of each EU country will be vaccinated against the virus faster and more efficiently.
As for Poland, according to the official government website, so far more than 12 million vaccinations have been performed in Poland, and 220,000 are performed daily. Currently, approximately 15 million doses have been delivered to Poland. By implementing both recommendations, the number of vaccine against COVID-19 doses delivered to EU countries is to increase significantly, which will also translate into the number of doses delivered to Poland.